Evidence map›Paper›PMID 35154162›Full record

ReviewFrontiers in immunology2022

CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair.

Anna J Jasinska, Ivona Pandrea, Cristian Apetrei

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. CCR5 marks a subset of mouse hematopoietic stem cells that are myeloid primed and expand with age.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Anna J JasinskaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
Ivona PandreaDepartment of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
Cristian ApetreiDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
University of Pittsburgh · US

Funding

SIV Pathogenesis in African Green Monkeys and Pigtailed MacaquesR01HL117715 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VASILE PANDREA, IVONA · 2012 to 2021
$7.0M
Interventions to Reduce Hypercoagulability in Old SIV-Infected NHPsR01HL123096 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VASILE PANDREA, IVONA · 2015 to 2025
$6.8M
Assessing the Role of GI Tract Dysfunction to HIV/SIV Disease ProgressionR01DK113919 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CRISTIAN APETREI, Ivona Vasile-Pandrea · 2017 to 2026
$5.7M
Immunology of Infectious DiseaseT32AI060525 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JoAnne L. Flynn · 2005 to 2026
$5.3M
New Strategy to Improve Gastrointestinal Health in SIV/HIVR01DK119936 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI APETREI, CRISTIAN · 2018 to 2022
$5.1M
Impact of metabolic programing of T cells from the GI tract and related tissues on HIV reservoir seeding, maintenance and reactivationR01DK131476 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CRISTIAN APETREI · 2021 to 2026
$3.9M
Animal Model for Testing SIV Latency Reversal StrategiesR01AI119346 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI APETREI, CRISTIAN · 2015 to 2019
$3.4M
PITT AIDS RESEARCH TRAINING PROGRAMT32AI065380 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BARRATT-BOYES, SIMON M · 2005 to 2020
$3.2M
Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted ImmunotherapyR01HL154862 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FEINSTEIN, MATTHEW JOEL, VASILE PANDREA, IVONA · 2020 to 2023
$3.1M
Mechanistic Studies of Gut Dysfunction Exacerbation due to SARS-CoV-2 in HIV/SIV infected IndividualsR01DK130481 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VASILE PANDREA, IVONA · 2021 to 2023
$1.2M
NHLBI NIH HHS R01 HL117715NHLBI NIH HHS R01 HL123096NHLBI NIH HHS R01 HL154862NIAID NIH HHS R01 AI119346NIAID NIH HHS T32 AI060525NIAID NIH HHS T32 AI065380NIDDK NIH HHS R01 DK113919NIDDK NIH HHS R01 DK119936NIDDK NIH HHS R01 DK130481NIDDK NIH HHS R01 DK131476
6 · The paper itself

Abstract

CCR5, a chemokine receptor central for orchestrating lymphocyte/cell migration to the sites of inflammation and to the immunosurveillance, is involved in the pathogenesis of a wide spectrum of health conditions, including inflammatory diseases, viral infections, cancers and autoimmune diseases. CCR5 is also the primary coreceptor for the human immunodeficiency viruses (HIVs), supporting its entry into CD4

Indexed as

Cell LineHIV-1HumansReceptors, CCR5Simian Immunodeficiency VirusCCR5 protein, humanReceptors, CCR5African green monkeyCCR5delta 32human immunodeficiency virusred-capped mangabeysimian immunodeficiency virussooty mangabeyvirus transmission

Identifiers

PMID35154162
PMCPMC8829453
OpenAlexW4210804900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.